Heat sensitivity of human parvovirus B19

被引:44
作者
Yunoki, M
Tsujikawa, M
Urayama, T
Sasaki, Y
Morita, M
Tanaka, H
Hattori, S
Takechi, K
Ikuta, K
机构
[1] Osaka Univ, Microbial Dis Res Inst, Dept Virol, Suita, Osaka 5650871, Japan
[2] Mitsubishi Pharma Corp, Div Pharmaceut Res, Prot Res Lab, Osaka, Japan
关键词
bioassay; parvovirus B19; plasma products; viral safety; virus inactivation;
D O I
10.1046/j.1423-0410.2003.00280.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background and Objectives To date there has been no published report on a systematic evaluation of the heat sensitivity of human parvovirus B19 (B19) and the related safety of the plasma-derived fractionated products. In this study, we examined the heat sensitivity of B19 by using the infectivity assay with cultured cells. Materials and Methods The heat sensitivity of B19 was examined by measuring the reduction in viral infectivity titres after heating liquid containing B19 at 60 degreesC. Viral infectivity was assayed by detection of viral antigens or viral mRNA in infected cells. As a control, canine parvovirus (CPV) was also heat-treated. Results B19 displayed quite different inactivation kinetics to CPV when both were heated in liquid at 60 degreesC. In sharp contrast to the latter, B19 was rapidly inactivated within 1 h when the virus was suspended in 5% or 25% human serum albumin solution, phosphate-buffered saline, or complete medium. However, B19 appeared to be resistant to heat inactivation in liquid containing 60% sucrose. Conclusions The heat sensitivity of B19 in liquid was clearly different from that of CPV. Significantly, the efficiency to inactivate B19 and reduce its infectivity following heating in liquid was mainly affected by the composition of the solutions used for virus suspension.
引用
收藏
页码:164 / 169
页数:6
相关论文
共 10 条
  • [1] Quantitative analysis of neutralizing immune responses to human parvovirus B19 using a novel reverse transcriptase polymerase chain reaction based assay
    Bostic, JR
    Brown, KE
    Young, NS
    Koenig, S
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1999, 179 (03) : 619 - 626
  • [2] *CPMP BWP BPWG, 1996, NOT GUID VIR VAL STU
  • [3] *CPMP BWP BPWG, 2001, WORKSH VIR SAF PLASM
  • [4] Infection of the erythroid cell line, KU812Ep6 with human parvovirus B19 and its application to titration of B19 infectivity
    Miyagawa, E
    Yoshida, T
    Takahashi, H
    Yamaguchi, K
    Nagano, T
    Kiriyama, Y
    Okochi, K
    Sato, H
    [J]. JOURNAL OF VIROLOGICAL METHODS, 1999, 83 (1-2) : 45 - 54
  • [5] NOVEL TRANSCRIPTION MAP FOR THE B19 (HUMAN) PATHOGENIC PARVOVIRUS
    OZAWA, K
    AYUB, J
    HAO, YS
    KURTZMAN, G
    SHIMADA, T
    YOUNG, N
    [J]. JOURNAL OF VIROLOGY, 1987, 61 (08) : 2395 - 2406
  • [6] Peddada L, 2000, TRANSFUSION, V40, p98S
  • [7] Human parvovirus B19 and blood products
    Prowse, C
    Ludlam, CA
    Yap, PL
    [J]. VOX SANGUINIS, 1997, 72 (01) : 1 - 10
  • [8] Detection of human parvovirus B19 DNA in plasma pools and blood products derived from these pools: Implications for efficiency and consistency of removal of B19 DNA during manufacture
    Saldanha, J
    Minor, P
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 1996, 93 (03) : 714 - 719
  • [9] Parvovirus B19 DNA in plasma pools and plasma derivatives
    Schmidt, I
    Blümel, J
    Seitz, H
    Willkommen, H
    Löwer, J
    [J]. VOX SANGUINIS, 2001, 81 (04) : 228 - 235
  • [10] NUCLEOTIDE-SEQUENCE AND GENOME ORGANIZATION OF HUMAN PARVOVIRUS B19 ISOLATED FROM THE SERUM OF A CHILD DURING APLASTIC CRISIS
    SHADE, RO
    BLUNDELL, MC
    COTMORE, SF
    TATTERSALL, P
    ASTELL, CR
    [J]. JOURNAL OF VIROLOGY, 1986, 58 (03) : 921 - 936